Promised EAP Date Approaching for Biogen's Highly Publicized ALS Drug

After the plight and advocacy of Lisa Stockman Mauriello drew the attention of a nation, Biogen made a promise to offer an expanded access program (EAP) for its investigational Amyotrophic Lateral Sclerosis (ALS drug), tofersen. The program is set to begin in mid-July, once patients from its Phase III VALOR trial transition from placebo to active treatment.